Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma

NCT06429150 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma
Plasmacytoma

Interventions

BIOLOGICAL: CAR-T cells

Sponsor

Shenzhen Geno-Immune Medical Institute

Collaborators

[object Object]